Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | PDE6D | O43924 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25935029 | 0.89 | FFAR4 (0.46) | FFAR4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL25819587 | 0.84 | CKS1B (0.43) | FFAR4KMT2ATP53 | |
| SCHEMBL25937000 | 0.83 | MAPT (0.44) | FFAR4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL30475482 | 0.83 | MAPT (0.44) | FFAR4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL25819309 | 0.82 | MAPT (0.47) | FFAR4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL25819203 | 0.81 | FFAR4 (0.61) | FFAR4 | |
| SCHEMBL25819440 | 0.81 | MAPT (0.46) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25935052 | 0.81 | MAPT (0.49) | FFAR4MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL25819206 | 0.80 | FFAR4 (0.51) | FFAR4MAPTALDH1A1 | |
| SCHEMBL25935028 | 0.79 | FFAR4 (0.49) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | FFAR4 4754/4885MAPT 2055/4885KDM4E 1918/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | FFAR4 4733/4885MAPT 1700/4885KDM4E 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.